Rani Therapeutics Holdings annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Rani Therapeutics Holdings Depreciation & Amortization Growth & History (RANI)
Rani Therapeutics Holdings's depreciation and amortization was $900,000 for fiscal 2025.
View full Rani Therapeutics Holdings company overviewRani Therapeutics Holdings annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $900,000 | −$128,000 | −12.45% |
| 2024 | 2024-12-31 | $1.0M | $206,000 | +25.06% |
| 2023 | 2023-12-31 | $822,000 | $274,000 | +50.00% |
| 2022 | 2022-12-31 | $548,000 | $51,000 | +10.26% |
| 2021 | 2021-12-31 | $497,000 | −$92,000 | −15.62% |
| 2020 | 2020-12-31 | $589,000 | — | — |
Rani Therapeutics Holdings quarterly depreciation and amortization
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $152,000 | −$88,000 | −36.67% |
| Q1 2026 | 2026-03-31 | $161,000 | −$90,000 | −35.86% |
| Q4 2025 | 2025-12-31 | $186,000 | — | — |
| Q3 2025 | 2025-09-30 | $223,000 | −$36,000 | −13.90% |
| Q2 2025 | 2025-06-30 | $240,000 | −$15,000 | −5.88% |
| Q1 2025 | 2025-03-31 | $251,000 | $3,000 | +1.21% |
| Q3 2024 | 2024-09-30 | $259,000 | $41,000 | +18.81% |
| Q2 2024 | 2024-06-30 | $255,000 | $66,000 | +34.92% |
| Q1 2024 | 2024-03-31 | $248,000 | $60,000 | +31.91% |
| Q3 2023 | 2023-09-30 | $218,000 | $77,000 | +54.61% |
| Q2 2023 | 2023-06-30 | $189,000 | $67,000 | +54.92% |
| Q1 2023 | 2023-03-31 | $188,000 | $77,000 | +69.37% |
| Q3 2022 | 2022-09-30 | $141,000 | $21,000 | +17.50% |
| Q2 2022 | 2022-06-30 | $122,000 | −$6,000 | −4.69% |
| Q1 2022 | 2022-03-31 | $111,000 | −$25,000 | −18.38% |
| Q3 2021 | 2021-09-30 | $120,000 | −$24,000 | −16.67% |
| Q2 2021 | 2021-06-30 | $128,000 | — | — |
| Q1 2021 | 2021-03-31 | $136,000 | — | — |
| Q3 2020 | 2020-09-30 | $144,000 | — | — |
Rani Therapeutics Holdings depreciation and amortization trends
Over the last five fiscal years, Rani Therapeutics Holdings's depreciation and amortization increased from $589,000 to $900,000, a change of $311,000. The latest reported quarter, Q2 2026, shows $152,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rani Therapeutics Holdings source filings ↗